Effect of (-)-epicatechin on the modulation of progression markers of chronic renal damage in a 5/6 nephrectomy experimental model.
Cell biology
Pathology
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
05
03
2019
revised:
29
03
2019
accepted:
03
04
2019
entrez:
27
4
2019
pubmed:
27
4
2019
medline:
27
4
2019
Statut:
epublish
Résumé
To evaluate the effects of (-)-epicatechin (Epi) in the progression of kidney damage. We assessed the effects of Epi [0.01-20 mg/kg of body weight/day] during 14 days, in a 5/6 nephrectomy model in mice. Nephrectomy-induced systolic arterial hypertension was significantly reduced in a dose dependent manner with Epi treatment. Increased serum creatinine and urea were reduced almost to normal values. The concentration of tetrahydrobiopterin (BH4), used as subrogate of endothelial dysfunction, decreased in nephrectomyzed animals, Epi treatment increased BH4 levels almost reaching normal values. The expression of angiotensin II receptor (AT Chronic kidney disease (CKD) is an independent cardiovascular risk factor associated with a mortality rate 10 to 20 times higher than that of the general population. High blood pressure, endothelial dysfunction and oxidative stress are important factors determining kidney damage progression. Findings of this study indicate that Epi is able to counteract the deleterious effects of subtotal nephrectomy and the structural and functional changes in the remnant kidney tissue, decreasing the progression of CKD. These results warrant the possibility of implement clinical trials to limit the progression of CKD in humans.
Identifiants
pubmed: 31025018
doi: 10.1016/j.heliyon.2019.e01512
pii: S2405-8440(19)32288-1
pii: e01512
pmc: PMC6475891
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e01512Références
Am J Physiol Renal Physiol. 2000 Feb;278(2):F173-9
pubmed: 10662721
Kidney Int. 2003 Jul;64(1):350-5
pubmed: 12787428
J Immunol Methods. 1992 Aug 10;152(2):227-36
pubmed: 1500732
Mol Cell Biochem. 2004 Apr;259(1-2):91-9
pubmed: 15124912
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Circ Res. 2006 Mar 31;98(6):717-9
pubmed: 16574911
Kidney Int. 2006 Dec;70(11):1914-9
pubmed: 16985515
J Renin Angiotensin Aldosterone Syst. 2008 Dec;9(4):196-201
pubmed: 19126659
Zhong Xi Yi Jie He Xue Bao. 2009 Jun;7(6):557-62
pubmed: 19583939
Curr Opin Pediatr. 2010 Apr;22(2):161-9
pubmed: 20090523
Hypertension. 2010 Jun;55(6):1398-405
pubmed: 20404222
Am J Nephrol. 2010;31(6):541-50
pubmed: 20484892
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Drug Discov Today Dis Models. 2010;7(1-2):13-19
pubmed: 21286234
Free Radic Biol Med. 2012 Jan 1;52(1):70-9
pubmed: 22001745
Nat Rev Nephrol. 2012 Feb 21;8(5):293-300
pubmed: 22349487
Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1264-74
pubmed: 22933302
Cochrane Database Syst Rev. 2012 Oct 17;10:CD008176
pubmed: 23076940
Front Physiol. 2013 May 13;4:105
pubmed: 23717285
J Am Soc Nephrol. 2013 Oct;24(10):1512-8
pubmed: 23970124
Food Funct. 2014 Mar;5(3):521-7
pubmed: 24458104
FEBS J. 2014 Dec;281(24):5567-80
pubmed: 25284161
Free Radic Biol Med. 2016 Jan;90:35-46
pubmed: 26569027
Lancet. 2017 Mar 25;389(10075):1238-1252
pubmed: 27887750
Redox Biol. 2017 Apr;11:342-349
pubmed: 28039839
Curr Opin Pediatr. 2018 Apr;30(2):247-251
pubmed: 29517980
Front Physiol. 2018 Apr 24;9:394
pubmed: 29740333
Med Sci Monit. 2018 Jul 10;24:4760-4766
pubmed: 29987270
Kidney Blood Press Res. 2018;43(4):1388-1407
pubmed: 30153666
Food Funct. 2019 Jan 22;10(1):26-32
pubmed: 30604799